How to choose frontline therapy for chronic myelogenous leukemia: So many drugs, not so many patients

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 1, 2012, Pages 112-118

  Shami, Paul J ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

BCR ABL; CML; Dasatinib; Imatinib; Nilotinib

Indexed keywords

ALPHA INTERFERON; CYTARABINE; DASATINIB; IMATINIB; NILOTINIB; PEGINTERFERON; PROTEIN TYROSINE KINASE INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE MUTATION; GLUCOSE BLOOD LEVEL; HUMAN; LOW DRUG DOSE; LYMPHOCYTOSIS; MEDICAL DECISION MAKING; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84855824539     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0010     Document Type: Review

References (35)

1. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172. (Pubitemid 29325745)
2. SEER Stat Fact Sheets: Chronic Myeloid Leukemia. National Cancer Institute Surveillance Epidemiology and End Results Web site. Available at: http://seer.cancer.gov/statfacts/html/cmyl.html. Accessed November 30, 2011.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. (Pubitemid 36302244)
4. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-1061.
5. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood 2009;114:462. Abstract 1126.
6. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
7. Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22:1963-1966.
8. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424-430.
9. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-1642.
10. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-2521.
11. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009;114:4933-4938.
12. Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-397.
13. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
14. Hochhaus A, Saglio G, le Coutre P, et al. Superior efficacy of nilotinib compared with imatinib in newly-diagnosed patients with chronic myeloid leukemia in chronic (CML-CP): ENESTnd minimum 24-month follow-up [abstract]. Haematologica 2011;96(Suppl 2):Abstract 0484.
15. Hughes TP, Hochhaus A, Saglio G, et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood 2010;116:Abstract 207.
16. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404.
17. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
18. Hochhaus A, Shah N, Cortes J, et al. Efficacy and safety of dasatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): minimum 24-month follow-up from the DASISION trial [abstract]. Haematologica 2011;96(Suppl 2):Abstract 1011.
19. Quintás-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914. (Pubitemid 47477268)
20. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212.
21. Porkka K, Baccarani M, Cortes J, et al. Pleural effusion in patients with chronic-phase chronic myeloid leukemia (CML-CP) who received first-line dasatinib in the DASISION trial: patient characteristics, management, and outcomes [abstract]. Haematologica 2011;96(Suppl 2):Abstract 0692.
22. Radich JP, Kopecky KJ, Kamel-Reid S, et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial [abstract]. Blood 2010;116:Abstract LBA6.
23. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417. (Pubitemid 44903745)
24. Baccarani M, Guilhot F, Larson RA, et al. Outcomes by cytogenetic and molecular response at 12 and 18 months of imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) in the IRIS trial [abstract]. Blood 2006;108:606a. Abstract 2138.
25. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141. (Pubitemid 40248339)
26. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-5797. (Pubitemid 43927133)
27. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505. (Pubitemid 40740783)
28. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-1029. (Pubitemid 47629897)
29. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T- and NK-cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-782.
30. Nagata Y, Ohashi K, Fukuda S, et al. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010;91:799-807.
31. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405.
32. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009;94:135-139.
33. Schiffer CA, Cortes JE, Saglio G, et al. Association of lymphocytosis following treatment with dasatinib with response and outcome [abstract]. J Clin Oncol 2010;28(15 Suppl):Abstract 6553.
34. Schiffer CA, Cortes JE, Saglio G, et al. Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib [abstract]. Blood 2010;116:Abstract 358.
35. O'Brien S, Berman E, Moore JO, et al. NCCN Task Force Report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011:9(Suppl 2):S1-25.